Answers are grounded in this paper and cite their sources.
Summary Twenty-four patients with Raynaud's phenomenon were treated with griseofulvin and a placebo in a double-blind cross-over clinical trial. The results were assessed subjectively and plotted sequentially. The number of patients able to distinguish the active from the placebo treatment was statistically significant (P=0·05). There were indications that the response was dose dependent. Further studies are needed to establish whether griseofulvin offers useful clinical improvement in this condition.
No takes yet. Share an insight, caveat, or question.
Sabri et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: